Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.46 +3.8%	$0.92	$0.51 ▼ $1.60	$81.12M	-0.2	62,636 shs	178,113 shs
IMMX Immix Biopharma	$2.78 -3.8%	$2.28	$1.26 ▼ $3.08	$77.50M	0.24	151,330 shs	166,742 shs
IMUX Immunic	$0.83 -1.2%	$0.83	$0.56 ▼ $2.11	$79.05M	1.49	979,200 shs	505,550 shs
VYNE VYNE Therapeutics	$1.30 -2.6%	$1.17	$0.85 ▼ $4.30	$19.70M	1.78	225,064 shs	128,791 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	-7.24%	+23.68%	+48.42%	+69.90%	+12.80%
IMMX Immix Biopharma	+9.06%	+10.31%	+22.98%	+72.02%	+36.97%
IMUX Immunic	+1.19%	+9.80%	+4.36%	-14.98%	-39.13%
VYNE VYNE Therapeutics	-6.34%	+3.10%	+47.88%	-26.92%	-37.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	3.1216 of 5 stars	3.5	3.0	3.0	2.5	0.6
IMMX Immix Biopharma	3.5884 of 5 stars	3.5	5.0	2.0	3.3	0.6
IMUX Immunic	2.6418 of 5 stars	3.6	1.0	3.0	2.5	0.6
VYNE VYNE Therapeutics	2.9949 of 5 stars	3.5	3.0	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.00	Buy	$7.00	378.14% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	151.80% Upside
IMUX Immunic	3.25	Buy	$11.60	1,297.59% Upside
VYNE VYNE Therapeutics	3.00	Buy	$6.25	382.63% Upside

Current Analyst Ratings Breakdown

Latest VYNE, IMMX, IMUX, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/25/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.75 ➝ $4.50
4/16/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$26.03M	3.12	N/A	N/A	$1.67 per share	0.88
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
VYNE VYNE Therapeutics	$500K	39.39	N/A	N/A	$3.53 per share	0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
VYNE VYNE Therapeutics	-$39.83M	-$0.99	N/A	N/A	N/A	-6,974.55%	-71.89%	-58.94%	8/13/2025 (Estimated)

Latest VYNE, IMMX, IMUX, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/8/2025	Q1 2025	VYNE VYNE Therapeutics	-$0.29	-$0.20	+$0.09	-$0.20	$0.05 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	10.25	10.25
IMMX Immix Biopharma	N/A	1.80	1.80
IMUX Immunic	N/A	0.74	0.74
VYNE VYNE Therapeutics	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
IMMX Immix Biopharma	11.26%
IMUX Immunic	51.82%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
IMMX Immix Biopharma	55.40%
IMUX Immunic	4.60%
VYNE VYNE Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable
VYNE VYNE Therapeutics	30	15.21 million	14.48 million	Not Optionable

VYNE, IMMX, IMUX, and CNTB Headlines

Recent News About These Companies

VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress

July 11, 2025 | insidermonkey.com

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% - Should You Sell?

July 8, 2025 | americanbankingnews.com

Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor

July 2, 2025 | fiercebiotech.comF

VYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis Trial

July 2, 2025 | quiverquant.comQ

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

July 2, 2025 | globenewswire.com

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges

May 31, 2025 | investing.com

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations

May 12, 2025 | finance.yahoo.com

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.

April 27, 2025 | nasdaq.com

VYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque Psoriasis

April 27, 2025 | nasdaq.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)

April 26, 2025 | markets.businessinsider.com

VYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025 | finanznachrichten.de

VYNE shares tumble after FDA clinical hold on psoriasis drug study

April 25, 2025 | za.investing.com

Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis

April 25, 2025 | biospace.comB

FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns

April 25, 2025 | fiercebiotech.comF

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

April 25, 2025 | benzinga.com

VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025 | globenewswire.com

Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

April 9, 2025 | finanznachrichten.de

Artiva Biotherapeutics Names New Chief Medical Officer

April 8, 2025 | marketwatch.com

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE, IMMX, IMUX, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.46 +0.05 (+3.83%)

As of 12:34 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Immix Biopharma NASDAQ:IMMX

$2.78 -0.11 (-3.81%)

As of 12:34 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immunic NASDAQ:IMUX

$0.83 -0.01 (-1.19%)

As of 12:33 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

VYNE Therapeutics NASDAQ:VYNE

$1.30 -0.04 (-2.63%)

As of 12:34 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time